Galactorrhea - Side effect of risperidone in combination with depakine chrono in a patient with bipolar disorder

Psychiatria Danubina

Volumn 22, Issue 1, 2010, Pages 125-127

  Peitl, Marija Vučić ^a   Peitl, Vjekoslav ^a   Grahovac, Tanja ^a   Pavlović, Eduard ^a  

^a KBC RIJEKA   (Croatia)

Author keywords

Bipolar disorder; Depakine chrono; Galactorrhea; Risperidone

Indexed keywords

CARBAMAZEPINE; LITHIUM; RISPERIDONE; VALPROIC ACID; ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT;

ADULT; ANAMNESIS; BIPOLAR DISORDER; CASE REPORT; CONFERENCE PAPER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; HUMAN; MOOD; NAUSEA; OSTEOPOROSIS; PSYCHOMOTOR RETARDATION; SIDE EFFECT; WEIGHT GAIN; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MIDDLE AGED;

ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GALACTORRHEA; HUMANS; MIDDLE AGED; RISPERIDONE; VALPROIC ACID;

EID: 77957674915     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic - induced hyperprolactinemia. Pharmacotherapy 2009; 29:64-73.
2. Chung YC, Eun HB. Hyperprolactinemia induced by risperidone. Int J Neuropychopharmacol 1998; 1:93-94.
3. Conley RR. Risperidone side effects. J Clin Psychiatry 2000; 61 Suppl 8:20-3.
4. Elenitza IM. Ednocrinologic adverse affects of psychotropic drugs. Vertex 2005; 16:43-8.
5. Haddad PN, Wieck A. Antipsychotic-included hyperprolactinemia: mechanisms, clinical features and management. Drugs 2004; 64:2291-314. (Pubitemid 39388605)
6. Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindemayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double - blind, fixed-dose study. J Clin Psychopharmacol 2008; 28:392-400.
7. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11:851-6.
8. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008; 172:177:97.
9. Molitch ME. Drug and prolactin. Pituitary 2008; 11:209-18.
10. Riecher-Rössler A, Schmid C, Bleuer S, Brikhäuser M. Antipsychotics and hyperprolactinemia: pathophysiology, clinical relevance, diagnosis and therapy. Neuropsychiatr 2009; 23:71-83.
11. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007; 3:929-51. (Pubitemid 350162092)
12. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomized controlled trial. Br J. Psychiatry 2003; 182:141-7. (Pubitemid 36177237)